Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe DiseaseBusiness Wire • 12/11/23
Press Release: Statement on FTC challenge to proposed license agreement with Maze TherapeuticsGlobeNewsWire • 12/11/23
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd aloneGlobeNewsWire • 12/11/23
Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the manufacture of Clexane®PRNewsWire • 12/10/23
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplantGlobeNewsWire • 12/07/23
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in ImmunologyGlobeNewsWire • 12/07/23
AQEMIA Announces a Major Multi-year Collaboration of $140 Million With SanofiBusiness Wire • 12/05/23
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease TreatmentBusiness Wire • 11/30/23
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future SalesInvestors Business Daily • 11/27/23
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious diseaseGlobeNewsWire • 11/27/23
CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortageCNBC • 11/17/23